Synthesis of thiazolidinedione compound library
Open accessAbstract
Thiazolidinediones (TZDs), also known as Glitazones, have anti-diabetic, anti-inflammatory and anti-cancer properties. A simple, efficient and cost-effective synthesis of a thiazolidinedione compound library was developed. The synthesis is facilitated by microwave irradiation in three of the four steps followed by reduction under pressurized hydrogen gas using palladium hydroxide. All reactions, except one, were completed within an hour and provided desired products in moderate to good yields after a simple work-up.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Troglitazone was the first thiazolidinedione approved by the FDA, but it was taken off the market after 3 years because some patients experienced serious liver toxicity.
“Troglitazone is the first TZDs drug that is approved by the FDA. However, it was taken off the market after 3 years as some patients’ experienced serious liver toxicity.”
Currently pioglitazone and rosiglitazone are the only thiazolidinedione medications available in the market for clinical use.
“Right now, pioglitazone and rosiglitazone are the only TZDs medications available in the market for clinical use.”
Thiazolidinediones (troglitazone, pioglitazone, and rosiglitazone) work by sensitizing insulin in type 2 diabetes mellitus.
“TZDs (troglitazone, pioglitazone and rosiglitazone) are also known as glitazones work by sensitizing insulin to T2DM.”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Risk of fracture with thiazolidinediones: An updated meta-analysis of randomized clinical trials
Zhu, Z.-N., Jiang, Y.-F., & Ding, T. (2014) · Bone · doi:10.1016/j.bone.2014.08.010 · Cited by 253 · see citing works
Flagged first, then by citations
Research works printed but not linked: 23
- Forouhi, N.G.; Wareham, N.J. Epidemiology of diabetes. Medicine 2010, 38, 602-606. [CrossRef] · DOI
- Shaw, J.E.; Sicree, R.A.; Zimmet, P.Z. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res. Clin. Pract. 2010, 87, 4-14. [CrossRef] [PubMed] · DOI · Paper page
- Sowers, J.R.; Epstein, M.; Frohlich, E.D. Diabetes, hypertension, and cardiovascular disease: An update. Hypertension 2001, 37, 1053-1059. [CrossRef] [PubMed] · DOI
- Chinthala, Y.; Kumar Domatti, A.; Sarfaraz, A.; Singh, S.P.; Kumar Arigari, N.; Gupta, N.; Satya, S.K.V.N.; Kotesh Kumar, J.; Khan, F.; Tiwari, A.K.; et al. Synthesis, biological evaluation and molecular modeling studies of some novel thiazolidinediones with triazole ring. Eur. J. Med. Chem. 2013, 70, 308-314. [CrossRef] · DOI
- Millioni, R.; Puricelli, L.; Iori, E.; Arrigoni, G.; Tessari, P. The effects of rosiglitazone and high glucose on protein expression in endothelial cells. J. Proteome Res. 2010, 9, 578-584. [CrossRef] · DOI
- Flowers, E.; Aouizerat, B.E.; Abbasi, F.; Lamendola, C.; Grove, K.M.; Fukuoka, Y.; Reaven, G.M. Circulating MicroRNA-320a and MicroRNA-486 Predict Thiazolidinedione Response: Moving Towards Precision Health for Diabetes Prevention. Metabolism 2015, 64, 1051-1059. [CrossRef] · DOI
- Hsu, J.C.; Ross-Degnan, D.; Wagner, A.K.; Zhang, F.; Lu, C.Y. How Did Multiple FDA Actions Affect the Utilization and Reimbursed Costs of Thiazolidinediones in US Medicaid? Clin. Ther. 2015, 37, 1420-1432. [CrossRef] · DOI
- Helal, M.A.; Darwish, K.M.; Hammad, M.A. Homology modeling and explicit membrane molecular dynamics simulation to delineate the mode of binding of thiazolidinediones into FFAR1 and the mechanism of receptor activation. Bioorg. Med. Chem. Lett. 2014, 24, 5330-5336. [CrossRef] · DOI
- Mohanty, P.; Aljada, A.; Ghanim, H.; Hofmeyer, D.; Tripathy, D.; Syed, T.; Al-Hadad, W.; Dhindsa, S.; Dandona, P. Evidence for a Potent Antiinflammatory Effect of Rosiglitazone. J. Clin. Endocrinol. Metab. 2004, 89, 2728-2735. [CrossRef] · DOI
- Keil, A.M.; Frederick, D.M.; Jacinto, E.Y.; Kennedy, E.L.; Zauhar, R.J.; West, N.M.; Tchao, R.; Harvison, P.J. Cytotoxicity of Thiazolidinedione-, Oxazolidinedione-and Pyrrolidinedione-Ring Containing Compounds in HepG2 Cells. Toxicol. In Vitro 2015, 29, 1887-1896. [CrossRef] · DOI
- Hoffmann, B.R.; El-Mansy, M.F.; Sem, D.S.; Greene, A.S. Chemical Proteomics-Based Analysis of Off-Target Binding Profiles for Rosiglitazone and Pioglitazone: Clues for Assessing Potential for Cardiotoxicity. J. Med. Chem. 2012, 55, 8260-8271. [CrossRef] · DOI
- Park, K.W.; Kang, J.; Park, J.J.; Yang, H.-M.; Kwon, Y.-W.; Lee, H.-Y.; Kang, H.-J.; Koo, B.-K.; Oh, B.-H.; Park, Y.-B.; et al. Thiazolidinedione usage is associated with decreased response to clopidogrel in DM patients. Int. J. Cardiol. 2013, 168, 608-610. [CrossRef] · DOI
- Mughal, A.; Kumar, D.; Vikram, A. Effects of Thiazolidinediones on metabolism and cancer: Relative influence of PPARgamma and IGF-1 signaling. Eur. J. Pharmacol. 2015, 768, 217-225. [CrossRef] · DOI
- Roussel, R.; Hadjadj, S.; Pasquet, B.; Wilson, P.W.F.; Smith, S.C., Jr.; Goto, S.; Tubach, F.; Marre, M.; Porath, A.; Krempf, M.; et al. Thiazolidinedione use is not associated with worse cardiovascular outcomes: A study in 28,332 high risk patients with diabetes in routine clinical practice. Int. J. Cardiol. 2013, 167, 1380-1384. [CrossRef] · DOI
- Sotiriou, A.; Blaauw, R.H.; Meijer, C.; Gijsbers, L.H.; van der Burg, B.; Vervoort, J.; Rietjens, I.M.C.M. Correlation between activation of PPARγ and resistin downregulation in a mouse adipocyte cell line by a series of thiazolidinediones. Toxicol. Vitr. 2013, 27, 1425-1432. [CrossRef] · DOI
- He, J.; Xu, C.; Kuang, J.; Liu, Q.; Jiang, H.; Mo, L.; Geng, B.; Xu, G. Thiazolidinediones attenuate lipolysis and ameliorate dexamethasone-induced insulin resistance. Metabolism 2015, 64, 826-836. [CrossRef] · DOI
- Sinagra, T.; Tamburella, A.; Urso, V.; Siarkos, I.; Drago, F.; Bucolo, C.; Salomone, S. Reversible inhibition of vasoconstriction by thiazolidinediones related to PI3K/Akt inhibition in vascular smooth muscle cells. Biochem. Pharmacol. 2013, 85, 551-559. [CrossRef] · DOI · Paper page
- Lecca, D.; Nevin, D.K.; Mulas, G.; Casu, M.A.; Diana, A.; Rossi, D.; Sacchetti, G.; Carta, A.R. Neuroprotective and anti- inflammatory properties of a novel non-thiazolidinedione PPARγ agonist in vitro and in MPTP-treated mice. Neuroscience 2015, 302, 23-35. [CrossRef] · DOI
- Molero, J.C.; Lee, S.; Leizerman, I.; Chajut, A.; Cooper, A.; Walder, K. Effects of rosiglitazone on intramyocellular lipid accumula- tion in Psammomys obesus. Biochim. Biophys. Acta 2010, 1802, 235-239. [CrossRef] · DOI
- Gaonkar, S.L.; Shimizu, H. Microwave-assisted synthesis of the antihyperglycemic drug rosiglitazone. Tetrahedron 2010, 66, 3314-3317. [CrossRef] · DOI
- Seaquist, E.R.; Miller, M.E.; Fonseca, V.; Ismail-Beigi, F.; Launer, L.J.; Punthakee, Z.; Sood, A. Effect of Thiazolidinediones and Insulin on Cognitive Outcomes in ACCORD-MIND. J. Diabetes Complicat. 2013, 27, 485-491. [CrossRef] [PubMed] · DOI
- Lidström, P.; Tierney, J.; Wathey, B.; Westman, J. Microwave Assisted Organic Synthesis-A Review. Tetrahedron 2001, 57, 9225-9283. [CrossRef] · DOI
- Hudzicki, J. Kirby-Bauer Disk Diffusion Susceptibility Test Protocol; American Society for Microbiology: Washington, DC, USA, 2009. Available online: https://asm.org/getattachment/2594ce26-bd44-47f6-8287-0657aa9185ad/Kirby-Bauer-Disk-Diffusion- Susceptibility-Test-Protocol-pdf.pdf (accessed on 17 May 2022).
Cited by
Sorted by citations
Tegegne, B. A., Adugna, A., Yenet, A., Yihunie Belay, W., Yibeltal, Y., Dagne, A., Hibstu Teffera, Z., Amare, G. A., Abebaw, D., Tewabe, H., et al. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1440456 · Cited by 61 · see citing works
- Authors
- Damkaci, F., Szymaniak, A. A., Biasini, J. P., & Cotroneo, R.
- Affiliations
- State University of New York at Oswego (US)
- Corresponding author
- Damkaci, Fehmi
- Venue
- Compounds
- Publisher
- MDPI AG
- Published
- 2022-07-05
- Volume
- 2
- Issue
- 3
- Pages
- 182-190
- ISSN
- 2673-6918 (ISSN-L)
- OpenAlex
- W4284709484
- Cited by
- 8
- References
- 1
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 3 · 2023: 1 · 2022: 1
- FWCI
- 0.67
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Compounds (publishedVersion, cc-by)
- Funders
- State University of New York
- National Institute of Advanced Industrial Science and Technology
- Topics
- Physical Sciences › Chemistry › Organic Chemistry › Synthesis and biological activity
- Physical Sciences › Chemistry › Organic Chemistry › Synthesis of heterocyclic compounds
- Physical Sciences › Chemistry › Organic Chemistry › Microwave-Assisted Synthesis and Applications
- Keywords
- thiazolidinediones, compound library synthesis, microwave-assisted synthesis, hydrogenation, antidiabetic drugs, anti-inflammatory agents, anticancer agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
